Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer

International Journal of Radiation Biology

Volumn 85, Issue 1, 2009, Pages 96-104

  Koukourakis, George V ^a   Baksevanis, Constantinos N ^b   Zambatis, Haralambos ^b   Gritzapis, Angelos ^b   Maltezos, Efstratios ^a   Simopoulos, Costantinos ^a   Koukourakis, Michael I ^a,c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c DUTh ^*  (Greece)

Author keywords

Amifostine; CD95; FAS; Head neck cancer; Radiotherapy; T lymphocytes

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FAS ANTIGEN; FLUOROURACIL; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROTECTION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HELPER CELL; HODGKIN DISEASE; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SUPPRESSOR CELL;

ADULT; AGED; AMIFOSTINE; ANTIGENS, CD56; ANTIGENS, CD95; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS;

EID: 60749109848     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000802635070     Document Type: Article

References (37)

1. Andrews GA. 1967. Radiation accidents and their management. Radiation Research Supply 7:390-397.
2. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E. 2006. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clinical Cancer Research 12:465-472.
3. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. 2004. External beam radiation of tumors alters phenotype of tumor cells to renderthem susceptible to vaccine-mediated T-cell killing. Cancer Research 64:4328-4337.
4. Daniel V, Weimer R, Schimpf K, Opelz G. 1989. Autoantibodies against CD4+ and CD8+ T- lymphocytes in HIV-infected hemophilia patients. Vox Sanguinis 57:172-176.
5. David H, Martin C. 1999. Practical longitudinal data analysis. Texts in Statistical Science Series. London: Chapman & Hall.
6. Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW. 2005. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Research 65:374.
7. Gray WC, Chrétien PB, Suter CM, Revie DR, Tomazic VT, Blanchard CL, Aygun C, Amornmarn R, Ordonez JV. 1985. Effect of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngology-head and Neck Surgery 93:650-659.
8. Hagen JH, Hanahan D. 1999. Tumor cells utilize multiple pathways to down modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Annals of the New York Academy of Sciences 887:150-163.
9. Houston A, O'Connell J. 2004. The Fas signalling pathway and its role in the pathogenesis of cancer. Current Opinion in Pharmacology 4:321-326.
10. Ioachim HL, Decuseara R, Giancotti F, Dorsett BH. 2005. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymphnode metastases. Pathology Research and Practice 200:743-751.
11. Ingey FH, Krammer PH. 2002. Death and anti-death: Tumor resistance to apoptosis. Nature Reviews Cancer 2:277-288.
12. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. 1991. The polypeptide encoded by the CDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243.
13. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. 2004. The role of Fas ligand and transforming growth factor beta in tumor progression: Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100:2281-2291.
14. Korsmeyer SJ. 1992. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 81:151-157.
15. Krammer PH, Galle PR, Moller P, Debatin KM. 1998. CD95 (APO-1/FAS)-mediated apoptosis in normal and malignant liver, colon and hematopoietic cells. Advanced Cancer Research 75:251-273.
16. Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V. 1998. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. European Journal of Cancer 34:838-844.
17. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. 2003. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/FAS and CD31 expressing T-cells in breast cancer patients. Cancer Immunology and Immunotherapy 52:127-131.
18. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. 2004. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clinical Cancer Research 10:3755-3762.
19. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. 1996. SAS system for mixed models. SAS institute.
20. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. 2007. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. Journal of Clinical Oncology 25:862-868.
21. Murakami M, Sasaki T, Yamasaki S, Kuwahara K, Miyata H, Chayama K. 2004. Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochemical and Biophysical Research Communications 319:114-119.
22. Murta EF, de Andrade JM, Falcao RP, Bighetti S. 2000. Lymphocyte subpopulation in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86:403-407.
23. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, Pissakas G, Kolitsi G, Kyprianou K, Kouloulias V, Papanikolaou I, Yiotakis I, Dardoufas K. 2003. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncology 39:397-401.
24. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. 1996. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Journal of Clinical Oncology 14:1071-1076.
25. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G. 2002. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunology 188:97-113.
26. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S. 2000. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal of Radiation Oncology Biology Physics 48:997-1006.
27. Scholz M, Cinatl J. 2005. Fas/FasL interaction: A novel immune therapy approach with immobilized biologicals. Medicinal Research Reviews 25:331-342.
28. Sheard MA. 2001. Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis. International Journal of Cancer 96:213-220.
29. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. The Journal of Experimental Medicine 201:1973-1985.
30. Somma P, Lo Muzio L, Mansueto G, Delfino M, Fabbrocini G, Mascolo M, Mignogna C, Di Benedetto M, Carinci F, De Lillo A, Pastore L, Serpico R, De Rosa G, Staibano S. 2005. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. International Journal of Immunopathology and Pharmacology 18:59-64.
31. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. 2000. FADD/MORT 1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599-609.
32. Suda T, Takahashi T, Golstein D, Nagata S. 1993. Molecular cloning and expression of the fas ligand a novel member of the tumor necrosis factor family. Cell 75:1169-1178.
33. Tarpley JL, Porvin C, Chretien PB. 1975. Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy. Cancer 35:638-644.
34. Tisch M, Heimlich F, Daniel V, Opelz G Maier. 1998. Cellular Immune defect caused by post-surgical radiation therapy in patients with head and neck cancer. Otolaryngology-head and Neck Surgery 119:412-417.
35. Uno M, Otsuki T, Yata K, Fujii T, Sakaguchi H, Akisada T, Hiratsuka J, Imajo Y, Harada T. 2002. Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation. International Journal of Oncology 20:617-622.
36. Yamanaka R, Tanaka R, Yoshida S, Mori H, Takeda N, Satoh M. 1993. Effects of ACNU and cranial irradiation on the mouse immune system. Neurologia medico- Chirurgica (Tokyo) 33:65-70.
37. Zar JH. 1996. Biostatistical analysis. Ecology 77(7):2266-2267.